ESC 365 - Changes in Cognitive Function in Patients with Subclinical Atrial Fibrillation Treated with Apixaban or Aspirin: A Sub-Study from the ARTESiA Trial

ESC Professional Premium Access

Changes in Cognitive Function in Patients with Subclinical Atrial Fibrillation Treated with Apixaban or Aspirin: A Sub-Study from the ARTESiA Trial

Session: Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies

Topic: Cognitive Function and Autonomy in Patients with Atrial Fibrillation

Speaker: Doctor L. Rivard (Montreal, CA)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Lena Rivard

Montreal Heart Institute, Montreal (Canada)

1 presentation

2 followers

4 more presentations in this session

Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71

Speaker: Doctor S. Patel (Boston, US)

Aspirin and hemocompatibility related adverse events after LVAD implantation in patients with diabetes mellitus, obesity and atrial fibrillation: the ARIES-HM3 randomized clinical trial

Speaker: Doctor N. Uriel (New York, US)

Efficacy and safety of anticoagulation in patients with device-detected atrial fibrillation by indication for acetylsalicylic acid therapy

Speaker: Professor R. Schnabel (Hamburg, DE)

The Association between Age and Clinical Outcomes in Patients with Subclinical Atrial Fibrillation Treated with Apixaban: Insights from the ARTESiA Trial

Speaker: Associate Professor M. Proietti (Milan, IT)

Access the full session

Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies

Speakers: Doctor L. Rivard, Doctor S. Patel, Doctor N. Uriel, Professor R. Schnabel, Associate Professor M. Proietti

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources